About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
MARIO
Community Infections
Pipeline
Publications and Presentations
Product
News
News
Events
Careers
Investors
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Invasive Fungal Infections
Invasive Candidiasis
Invasive Aspergillosis
MARIO
Community Infections
Vulvovaginal Candidiasis
Recurrent VVC
Pipeline
Publications and Presentations
Our Science
Publications and Presentations
Date
Title
September 2025
SCY-247 demonstrates high
in vitro
activity against genetically diverse
C. auris
isolates, including
FKS1
mutants
TIMM, September 2025
September 2025
Three Months of SCY-247 EUCAST MIC Testing: Uniform Activity against
Candida
Species and no Cross-Resistance to Echinocandins
TIMM, September 2025
September 2025
Efficacy of once or twice daily oral SCY-247, a second-generation triterpenoid antifungal, in a murine model of
Candida auris
infection
TIMM, September 2025
September 2025
In vitro
Efficacy of Second-Generation Triterpenoid Antifungal, SCY-247, against Multidrug- and Pandrug-resistant
Candida auris
TIMM, September 2025
September 2025
In vitro
activity of SCY-247 and comparators against clinical isolates of
Aspergillus spp
. and
Lomentospora prolificans
TIMM, September 2025
September 2025
The Novel Second-Generation IV/Oral Triterpenoid SCY-247 Maintains
In vitro
and
In vivo
Activity against Resistant
Candida glabrata
TIMM, September 2025
April 2025
Antifungal susceptibility testing of SCY-247 against contemporary clinical yeast isolates
ESCMID, April 2025
April 2025
SCY-247, a novel antifungal, demonstrates
in vitro
activity against genetically diverse
Candida auris
isolates, including
FKS1
mutants
ESCMID, April 2025
April 2025
The new triterpenoid antifungal SCY-247 retained activity against most echinocandin and fluconazole-resistant
Candida
spp isolates: reduced susceptibility against
C. glabrata
isolates showing substitutions at the first amino acid in hotspot 1
FKS2
gene
ESCMID, April 2025
April 2025
Assessment of
in vitro
activity of the new triterpenoid antifungal, SCY-247, against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024
ESCMID, April 2025
< Prev
Next >
×